Forteo ® (teriparatide [rDNA origin] injection)

20-mcg daily dose in a 2.4-mL prefilled delivery device

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Fracture Risk Reduction with FORTEO® (teriparatide [rDNA origin] injection) Treatment

Forteo reduced the risk of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis

Compared to placebo, Forteo® (teriparatide [rDNA origin] injection) treatment significantly reduced the risk of

  • incident vertebral fractures, and

  • incident nonvertebral fractures (Table 1) (Forteo Package Insert, 2012).

Teriparatide was effective in reducing the risk for vertebral fractures regardless of age, baseline rate of bone turnover, or baseline BMD (Forteo Package Insert, 2012).

Table 1. Effect of teriparatide on risk of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis (Forteo Package Insert, 2012)

ap<.001 compared to placebo

bp<.05 compared to placebo

Enclosed Prescribing Information

FORTEO® (teriparatide [rDNA origin] injection), Lilly

The published references below are available upon request by contacting 1-800-LillyRx.

References

FORTEO® [Package Insert]. Indianapolis, IN: Eli Lilly and Company; 2012.

Date of Last Review: February 12, 2017

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 8pm ET

Or you can

Ask us a question Chat with us

Submit a question

Visit Us @LillyMedical